Core Viewpoint - The article discusses the advancements in the biosynthesis of 1,4-butanediol (BDO) through engineered Escherichia coli, highlighting the challenges and breakthroughs in creating a sustainable production method without antibiotics or inducers [2][3][7]. Group 1: BDO Production Challenges - BDO biosynthesis faces three main challenges: lack of natural BDO-producing microorganisms, significant carbon loss during synthesis, and high dependency on antibiotics and inducers, leading to increased costs [3]. Group 2: Engineering Breakthroughs - Researchers at Zhejiang University have developed a high-efficiency BDO synthesis strain by systematically engineering E. coli, resulting in a production of 0.1 g/L of BDO initially, which was later optimized to 0.82 g/L [6]. - The optimal enzyme combination for BDO production was identified, including enzymes from various bacteria, and a mutant enzyme variant was created that increased BDO yield by 11.19 times [6]. - By knocking out the pdhR gene, the researchers enhanced the conversion efficiency of pyruvate to acetyl-CoA, significantly reducing pyruvate accumulation and increasing BDO yield by 44% to 1.83 g/L [6]. Group 3: Antibiotic-Free Fermentation System - A significant advancement was the development of an antibiotic-free fermentation system, where the researchers utilized E. coli's native transcriptional regulatory elements to drive BDO synthesis without external inducers [7]. - The engineered strain B21-pT19 achieved a remarkable BDO production of 34.63 g/L in a 5 L reactor over 72 hours, maintaining stable yields across multiple fermentation batches without the need for antibiotics or inducers, marking the highest reported level of BDO production to date [7].

Report Summary 1. Report Industry Investment Rating No information provided. 2. Core Viewpoints - The company adheres to the development mission of empowering global agriculture with biological and digital technologies, focusing on the "biotechnology + digital technology" dual - wheel drive for global agricultural modernization transformation, aiming to become a leading global agricultural technology service enterprise [25][26][28]. - In 2025 H1, the company achieved stable business development, with overall revenue of 684.5976 million yuan, a year - on - year increase of 6.50%. The modern agriculture business achieved revenue of 122.3698 million yuan, a year - on - year increase of 13.31% [28][31][34]. - The company will continue to deepen its global strategic layout, optimize resource allocation, upgrade product structure, and improve operational efficiency to enhance profitability and sustainable development capabilities [31][36]. 3. Summary by Directory 3.1. Research Basic Situation - Research object: Fubang Co., Ltd. - Industry: Fertilizer industry - Reception time: August 26, 2025 - Reception personnel: Company's chairman and general manager Wang Renzong, independent director Guo Fei, deputy general manager and financial controller Wan Gang, deputy general manager and board secretary Yi Min [16] 3.2. Detailed Research Institutions - The reception objects are investors who participated in the company's 2025 semi - annual online performance briefing through the Panorama Network live interactive platform [19]. 3.3. Research Institution Proportion No information provided. 3.4. Main Content Data - **Agro - chemical Auxiliary Business**: In 2025 H1, the auxiliary business won the title of "No. 1 in global fertilizer auxiliary sales" by Sullivan, achieving revenue of 496.4149 million yuan, a year - on - year increase of 5.62%. The company promotes transformation and upgrading, focusing on R & D of customized products in the domestic market and expanding overseas markets through localization operations [23]. - **Core Technologies and Products**: The company focuses on technological innovation, researching and applying new materials, and launching products and service models in biological and digital agriculture, aiming to build a modern agricultural ecosystem [24]. - **Land Transfer**: The company built a digital agriculture industrial park in Sanhe Town, Yingcheng City, introducing intelligent technologies in facility agriculture [25]. - **Modern Agriculture Business Strategy**: The biological agriculture segment focuses on four product areas and builds a full - chain R & D system. The digital agriculture segment provides full - process products and services, aiming to build a modern agricultural ecosystem [26]. - **Digital Economy Layout**: The company responds to national strategies, introduces advanced technologies, and sets up the "Tomato Commune" as a demonstration park [26][27]. - **Performance of Modern Agriculture Business**: In 2025 H1, it achieved revenue of 122.3698 million yuan, a year - on - year increase of 13.31%. It made progress in R & D, market expansion, and established a new marketing model [28]. - **Digital Agriculture Layout**: The company focuses on "biotechnology + digital technology", and has advantages in digital soil testing, intelligent water and fertilizer management, and orchard yield estimation [29]. - **Sub - company Wuhan Sotu Data Technology Co., Ltd.**: It developed a "soil digital map" and related digital solutions, currently in the demonstration application stage [30]. - **Overseas Cooperative Organization**: The company established Forbon Technology Netherlands Holdings Co. Cooperatief U.A. in the Netherlands in 2015 to promote international cooperation and business development [30]. - **2025 H1 Operating Performance**: The company achieved revenue of 684.5976 million yuan, a year - on - year increase of 6.50%. Domestic revenue was 365.0579 million yuan, a year - on - year increase of 5.10%, accounting for 53.32% of total revenue; overseas revenue was 319.5397 million yuan, a year - on - year increase of 8.16%, accounting for 46.68% of total revenue [31]. - **Exchange Rate Risk Management**: The company uses natural hedging and diversified settlement strategies to reduce the impact of exchange rate fluctuations [32]. - **Auxiliary Business R & D**: The company focuses on R & D of high - efficiency and environmentally friendly auxiliary products and promotes frontier project research [33]. - **Investment in Wuhan Shuanglvyuan Chuangxin Technology Co., Ltd.**: It developed a leading genomic intelligent breeding system based on biological breeding gene chips [33]. - **Market Promotion of Biological Agriculture Products**: The company's products in biological agriculture are in the demonstration and verification stage, and the "Tianshengdan" project is being promoted [34]. - **Reasons for Net Profit Decline in 2025 H1**: The company increased strategic investment, promoted large - scale demonstration projects, and faced impacts from overseas market expansion [34][35][36]. - **Measures to Address Financial Risks**: The company will improve the capital management system, evaluate goodwill regularly, and actively communicate with the market [36].

Core Insights - The research published in the journal "Nature Chemistry" reveals that E. coli can convert a molecule derived from waste plastic bottles into the painkiller acetaminophen, suggesting a sustainable method to upgrade plastic waste into useful products [1][2] Group 1: Research Findings - Plastic waste is an increasingly serious issue, and upgrading it sustainably remains a primary task [1] - The study utilized metabolic engineering to combine chemical reaction networks used in biological cells to produce desired molecules, although the effectiveness of this approach in upgrading plastic into useful products was previously unclear [1] - The research identified a chemical reaction called rearrangement catalyzed by phosphate in E. coli, which produces nitrogen-containing organic compounds essential for cell metabolism [1] Group 2: Production Efficiency - The study demonstrated that the molecule derived from plastic can serve as a starting material for producing acetaminophen in E. coli, achieving a yield of 92% [2] - The authors suggest that this research may be the first instance of generating acetaminophen from waste using E. coli, indicating potential for further exploration of other bacteria or plastics to produce useful products [2]

证券代码：688639 证券简称：华恒生物 公告编号：2025-023 安徽华恒生物科技股份有限公司 （三）本次投资事项不构成关联交易，亦不构成《上市公司重大资产重组管理 办法》规定的重大资产重组情形。 二、投资协议主体的基本情况 投资协议对方：安徽长丰(双凤)经济开发区管理委员会 对外投资公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 安徽华恒生物科技股份有限公司（以下简称"公司"）为保持公司行业领先地 位，实现公司的可持续发展，满足市场对高品质、低成本产品的需求，提高公司产 品的市场竞争力，拟投资人民币3.2亿元，建设"人工智能精准发酵及蛋白质工程共 享示范项目"（以下简称"项目"）。本次投资项目资金来源主要为自有或自筹资 金。预计建设期为36个月，项目建设地点位于长丰县双凤经济开发区双凤路与颍州 路交口东北角。 （二）对外投资的决策和审批程序 公司于2024年5月25日与安徽长丰(双凤)经济开发区管理委员会签订了金额为 此项目在公司管理层审批权限内，已经公司总经理办公会批准通过，无需提交董事 会 ...